• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Acumen Pharmaceuticals Inc. (Amendment)

    2/14/23 4:24:08 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABOS alert in real time by email
    SC 13G/A 1 abos-sc13ga_123122.htm AMENDMENT TO FORM SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND

    (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2

     

    (Amendment No. 1)*

    Acumen Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    00509G209

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)

     

      ☐ Rule 13d-1(c)

     

      ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    CUSIP No. 00509G209 13G Page 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Paul B. Manning

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    2,547,1431

    6

    SHARED VOTING POWER

    657,9852

    7

    SOLE DISPOSITIVE POWER

    2,547,1431

    8

    SHARED DISPOSITIVE POWER

    657,9852

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,205,1283

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.8%4

    12

    TYPE OF REPORTING PERSON*

    IN

     

    1 Consists of 2,547,143 shares of the Issuer's common stock held by The Paul B. Manning Revocable Trust dated May 10, 2000.
    2 The securities are held by BKB Growth Investments, LLC.
    3 Consists of: (i) 2,547,143 shares of the Issuer’s common stock held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 and (ii) 657,985 shares of the Issuer’s common stock held by BKB Growth Investments, LLC.

    4 This percentage is calculated based upon 40,925,284 shares of the Issuer’s common stock outstanding as of November 11, 2022, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2022, filed with the Securities and Exchange Commission on November 14, 2022.

     

     

     

     

    CUSIP No. 00509G209 13G Page 3 of 8 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    The Paul B. Manning Revocable Trust dated May 10, 2000

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Virginia

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    2,547,143

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    2,547,143

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,547,143

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.2%5

    12

    TYPE OF REPORTING PERSON*

    OO

      

    5 This percentage is calculated based upon 40,925,284 shares of the Issuer’s common stock outstanding as of November 11, 2022, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2022, filed with the Securities and Exchange Commission on November 14, 2022.

     

     

     

     

     

     

    CUSIP No. 00509G209 13G Page 4 of 8 Pages

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    BKB Growth Investments, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    657,985

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    657,985

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    657,985

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.6%6

    12

    TYPE OF REPORTING PERSON*

    OO

     

    6 This percentage is calculated based upon 40,925,284 shares of the Issuer’s common stock outstanding as of November 11, 2022, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2022, filed with the Securities and Exchange Commission on November 14, 2022.

     

     

     

     

     

     

    CUSIP No. 00509G209 13G Page 5 of 8 Pages

     

    Item 1.

     

      (a) Name of Issuer

    Acumen Pharmaceuticals, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

    427 Park St.
    Charlottesville, VA 22902

     

    Item 2.

     

      (a) Name of Person Filing

    Paul B. Manning
    The Paul B. Manning Revocable Trust dated May 10, 2000

    BKB Growth Investments, LLC

     

      (b) Address of Principal Business Office or, if none, Residence

    c/o PBM Capital Group, LLC
    200 Garrett Street, Suite S
    Charlottesville, VA 22902

     

      (c) Citizenship

    Paul B. Manning is a United States Citizen.
    The Paul B. Manning Revocable Trust dated May 10, 2000 is governed under the laws of the Commonwealth of Virginia
    .

    BKB Growth Investments, LLC is a Delaware limited liability company.

     

      (d) Title of Class of Securities

    Common Stock

     

      (e) CUSIP Number

    00509G209

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: NOT APPLICABLE.
       

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

     

     

     

     

     

    CUSIP No. 00509G209 13G Page 6 of 8 Pages

     

    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership.
       

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned: See responses to Item 9 on the attached cover pages.
      (b) Percent of class: See the responses to Item 11 on the attached cover pages.
      (c) Number of shares as to which the person has:
         
      (i) Sole power to vote or to direct the vote – See the responses to Item 5 on the attached cover pages.
      (ii) Shared power to vote or to direct the vote – See the responses to Item 6 on the attached cover pages.
      (iii) Sole power to dispose or to direct the disposition of – See the responses to Item 7 on the attached cover pages.
      (iv) Shared power to dispose or to direct the disposition of – See the responses to Item 8 on the attached cover pages.
             

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       

    Not Applicable

     

     

     

     

     

     

    CUSIP No. 00509G209 13G Page 7 of 8 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
       

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group.
       

    Not Applicable

     

    Item 9. Notice of Dissolution of Group.
       

    Not Applicable

     

    Item 10. Certification
       

    Not Applicable.

     

     

     

     

     

    CUSIP No. 00509G209 13G Page 8 of 8 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2023    
         
      /s/ Paul B. Manning  
      Paul B. Manning  
         
      The Paul B. Manning Revocable Trust Dated May 10, 2000  
         
      By: /s/ Paul B. Manning  
      Name: Paul B. Manning  
      Title: Trustee  
           
      BKB Growth Investments, LLC  
         
         
      By Tiger Lily Capital, LLC, its manager  
         
      By: /s/ Paul B. Manning  
      Name: Paul B. Manning  
      Title: Manager  
           
      By: /s/ Bradford Manning  
      Name: Bradford Manning  
      Title: Manager  
         

     

     

     

     

     

    Get the next $ABOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABOS

    DatePrice TargetRatingAnalyst
    7/26/2024$7.00Buy
    Citigroup
    12/12/2023$8.00Buy
    Deutsche Bank
    7/20/2023$9.00 → $14.00Buy
    BofA Securities
    5/18/2023$13.00Overweight
    Cantor Fitzgerald
    7/15/2022$15.00Buy
    BTIG Research
    6/30/2022$15.00Buy
    H.C. Wainwright
    1/21/2022$16.00 → $14.00Neutral → Buy
    B of A Securities
    7/26/2021$27.00Buy
    UBS
    More analyst ratings

    $ABOS
    Financials

    Live finance-specific insights

    See more
    • Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

      Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026 Cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025, expected to support current clinical and operational activities into early 2027  Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD)

      5/13/25 7:00:00 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

      NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2025 financial results on Tuesday, May 13, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at l

      5/6/25 4:00:00 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

      Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease Anticipate topline results in late 2026 Topline results from the Phase 1 study investigating a subcutaneous sabirnetug formulation support further development of this dosing option for patientsCash, cash equivalents and marketable securities of $231.5 million as of Dec. 31, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a

      3/27/25 7:00:00 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Acumen Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)

      2/14/24 8:32:42 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Acumen Pharmaceuticals Inc.

      SC 13G - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)

      2/6/24 9:02:25 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Acumen Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)

      1/24/24 4:22:26 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Acumen Pharmaceuticals with a new price target

      Citigroup initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $7.00

      7/26/24 7:19:00 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Acumen Pharmaceuticals with a new price target

      Deutsche Bank initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $8.00

      12/12/23 6:44:55 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities resumed coverage on Acumen Pharmaceuticals with a new price target

      BofA Securities resumed coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $14.00 from $9.00 previously

      7/20/23 7:18:27 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

      Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026 Cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025, expected to support current clinical and operational activities into early 2027  Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD)

      5/13/25 7:00:00 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

      NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET. The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that target

      5/7/25 4:00:00 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

      NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2025 financial results on Tuesday, May 13, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at l

      5/6/25 4:00:00 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABOS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.

      10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)

      5/13/25 4:36:39 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)

      5/13/25 7:32:31 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Acumen Pharmaceuticals Inc.

      DEFA14A - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)

      4/23/25 4:23:58 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABOS
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lucy Therapeutics Appoints Kim Drapkin as Board Chair

      Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st

      10/15/24 8:00:00 AM ET
      $ABOS
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

      CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today the appointment of James Doherty, Ph.D., as President and Chief Development Officer, effective February 1, 2024, reporting to Daniel O'Connell, Chief Executive Officer. Dr. Doherty's responsibilities will include oversight of clinical and non-clinical development, chemistry, manufacturing & controls and regulatory functions. "We are extremely excited to welcome Jim, who brings extensive experience and demonstrat

      2/1/24 7:00:00 AM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO & Chief Business Officer Zuga Matt sold $56,620 worth of shares (33,266 units at $1.70), decreasing direct ownership by 13% to 231,744 units (SEC Form 4)

      4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

      1/23/25 9:19:28 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Oconnell Daniel Joseph sold $20,102 worth of shares (12,619 units at $1.59), decreasing direct ownership by 2% to 667,488 units (SEC Form 4)

      4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

      1/23/25 5:18:02 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Legal Officer & Corp Sec Meisner Derek M sold $5,435 worth of shares (3,418 units at $1.59), decreasing direct ownership by 2% to 161,127 units (SEC Form 4)

      4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

      1/23/25 5:16:46 PM ET
      $ABOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care